Novel therapies blocking the renin–angiotensin–aldosterone system in the management of hypertension and related disorders
暂无分享,去创建一个
[1] M. Huentelman,et al. ACE2: A novel therapeutic target for cardiovascular diseases. , 2006, Progress in biophysics and molecular biology.
[2] Y. Liao,et al. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. , 2006, Cellular & molecular immunology.
[3] Ling Yu,et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. , 2006, Kidney international.
[4] J. A. Oliver,et al. Receptor-mediated actions of renin and prorenin. , 2006, Kidney international.
[5] M. Raizada,et al. Potential of gene therapy strategy for the treatment of hypertension. , 2006, Hypertension.
[6] G. Wolf. "As time goes by": angiotensin II-mediated transactivation of the EGF receptor comes of age. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] M. Huentelman,et al. Protection from angiotensin II‐induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats , 2005, Experimental physiology.
[8] L. Ruilope,et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. , 2005, American heart journal.
[9] M. Wellner,et al. Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats , 2005, Hypertension.
[10] M. Peiris,et al. Good ACE, bad ACE do battle in lung injury, SARS , 2005, Nature Medicine.
[11] Shunqiang Li,et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach , 2005, Nature Medicine.
[12] Arthur S Slutsky,et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.
[13] J. Yatabe,et al. Differential Effects of Angiotensin II Type-1 Receptor Antisense Oligonucleotides on Renal Function in Spontaneously Hypertensive Rats , 2005, Hypertension.
[14] V. Dzau. The cardiovascular continuum and renin–angiotensin–aldosterone system blockade , 2005, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[15] R. Schmieder,et al. Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients , 2005, Circulation.
[16] G. Mancia,et al. Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection , 2005, Blood pressure.
[17] J. Tait,et al. Konstitution des Aldosterons, des neuen Mineralocorticoids , 1954, Experientia.
[18] G. Williams. Aldosterone Biosynthesis, Regulation, and Classical Mechanism of Action , 2005, Heart Failure Reviews.
[19] R. Gilbert,et al. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. , 2004, Kidney international.
[20] J. Granger,et al. Antisense oligodeoxynucleotides directed against a novel angiotensinogen mRNA-stabilizing protein reduce blood pressure in spontaneously hypertensive rats. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.
[21] B. Kemp,et al. Platelet-Derived Growth Factor Receptor Transactivation Mediates the Trophic Effects of Angiotensin II In Vivo , 2004, Hypertension.
[22] W. Frishman,et al. Aldosterone and aldosterone antagonism in systemic hypertension , 2004, Current hypertension reports.
[23] R. Iliescu,et al. Expression of an angiotensin-( 1 – 7 )-producing fusion protein produces cardioprotective effects in rats , 2004 .
[24] L. Ruilope,et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. , 2004, The American journal of cardiology.
[25] Joël Ménard,et al. The 45-year story of the development of an anti-aldosterone more specific than spironolactone , 2004, Molecular and Cellular Endocrinology.
[26] A. Rudolph,et al. Aldosterone target organ protection by eplerenone , 2004, Molecular and Cellular Endocrinology.
[27] J. Nehmé,et al. Aldosterone-synthase overexpression in heart: a tool to explore aldosterone’s effects , 2004, Molecular and Cellular Endocrinology.
[28] F. Magrini,et al. Cardiovascular risk stratification according to the 2003 ESH‐ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria , 2004, Blood pressure.
[29] Morris J. Brown,et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. , 2003, Clinical science.
[30] T. Resink,et al. The renin-angiotensin system and extracellular matrix , 2004, The clinical investigator.
[31] A. Stanton,et al. Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren , 2003, Hypertension.
[32] H. Krum,et al. Can Renin Status Predict the Antihypertensive Efficacy of Eplerenone Add‐On Therapy? , 2003, Journal of clinical pharmacology.
[33] M. F. Booth,et al. What brings pericytes to tumor vessels? , 2003, The Journal of clinical investigation.
[34] N. Reichek,et al. Hypertension and Left Ventricular Hypertrophy : The 4 E Effects of Eplerenone , Enalapril , and Eplerenone / Enalapril in Patients With Essential , 2003 .
[35] Alice Stanton,et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.
[36] W. White,et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. , 2003, The American journal of cardiology.
[37] Matthew Ducar,et al. Novel Peptide Inhibitors of Angiotensin-converting Enzyme 2* , 2003, The Journal of Biological Chemistry.
[38] W. White,et al. Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension , 2003, Hypertension.
[39] S. Oparil,et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. , 2003, Journal of the American College of Cardiology.
[40] M. Mulvany,et al. Pressure-Induced Activation of Extracellular Signal-Regulated Kinase 1/2 in Small Arteries , 2003, Hypertension.
[41] G. Nguyen,et al. The renin receptor: the facts, the promise and the hope , 2003, Current opinion in nephrology and hypertension.
[42] James M. Gavin,et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. , 2002, Journal of the American Chemical Society.
[43] R. Abdi,et al. Angiotensin II Receptor Blocker‐Associated Angioedema: On the Heels of ACE Inhibitor Angioedema , 2002, Pharmacotherapy.
[44] M. Burnier,et al. Renal Hemodynamic and Natriuretic Effects of Concomitant Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Men , 2002, Hypertension.
[45] R. Califf,et al. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) , 2002, Circulation.
[46] H. Krum,et al. Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients , 2002, Hypertension.
[47] M. Crackower,et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.
[48] G. Nguyen,et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.
[49] T. Parsons,et al. Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.
[50] V. Buckalew,et al. OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria , 2002 .
[51] P. Conlin,et al. OR-55: Comparison of eplerenone and losartan in patients with low-renin hypertension , 2002 .
[52] G. Wuerzner,et al. Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril , 2002, Hypertension.
[53] G. Sagnella. Vasopeptidase inhibitors. , 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[54] J. Rouleau,et al. Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? , 2001, Circulation.
[55] R. Tabrizchi. Omapatrilat. Bristol-Myers Squibb. , 2001, Current opinion in investigational drugs.
[56] K. Robison,et al. A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.
[57] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[58] Yuji Saito,et al. Angiotensin II Induces Transactivation of Two Different Populations of the Platelet-derived Growth Factor β Receptor , 2000, The Journal of Biological Chemistry.
[59] J. Delyani. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. , 2000, Kidney international.
[60] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[61] M. Shibuya,et al. Angiotensin II type 1 receptor-induced extracellular signal-regulated protein kinase activation is mediated by Ca2+/calmodulin-dependent transactivation of epidermal growth factor receptor. , 1998, Circulation research.
[62] H. Kawakatsu,et al. Calcium-dependent Epidermal Growth Factor Receptor Transactivation Mediates the Angiotensin II-induced Mitogen-activated Protein Kinase Activation in Vascular Smooth Muscle Cells* , 1998, The Journal of Biological Chemistry.
[63] J. Ménard,et al. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. , 1997, Circulation.
[64] J. Babin-Ebell,et al. The renin-angiotensin system and vascular function. The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. , 1997 .
[65] I. Miyamori,et al. Vascular aldosterone in genetically hypertensive rats. , 1997, Hypertension.
[66] H. Buikema,et al. The renin-angiotensin system and vascular function. The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. , 1997, Heart and vessels.
[67] T. Hostetter,et al. Role of aldosterone in the remnant kidney model in the rat. , 1996, The Journal of clinical investigation.
[68] C. Chang,et al. Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-beta receptor protein expressions. , 1996, Journal of the American Society of Nephrology : JASN.
[69] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[70] J. Egido. Vasoactive hormones and renal sclerosis. , 1996, Kidney international.
[71] C. Brilla,et al. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. , 1995, European heart journal.
[72] C. Delcayre,et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. , 1995, Hypertension.
[73] M. Young,et al. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. , 1995, The American journal of physiology.
[74] C. Benjamin,et al. Convergence of Angiotensin II and Platelet-derived Growth Factor Receptor Signaling Cascades in Vascular Smooth Muscle Cells (*) , 1995, The Journal of Biological Chemistry.
[75] W. Frishman,et al. Renin Inhibition: A New Approach to Cardiovascular Therapy , 1994, Journal of clinical pharmacology.
[76] D. Gómez-Garre,et al. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[77] S. Kagami,et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. , 1994, The Journal of clinical investigation.
[78] J. Sadoshima,et al. Critical Role of the AT1 Receptor Subtype , 2005 .
[79] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[80] A. Vollmar,et al. Degradation and clearance of atrial natriuretic factors (ANF). , 1990, Life sciences.
[81] C. Johnston,et al. Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists. , 1989, The American journal of medicine.
[82] J. Michel,et al. Immunological approach to blockade of the renin-substrate reaction , 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[83] M. Peach,et al. Angiotensin II Induces Hypertrophy, not Hyperplasia, of Cultured Rat Aortic Smooth Muscle Cells , 1988, Circulation research.
[84] H. Gavras,et al. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. , 1982, American heart journal.